Gilead Sciences
30-Second Executive Brief
Executive Assessment
Gilead Sciences functions as an established institution within Healthcare & Life Sciences, backed by 47% sourcing coverage, with accelerating strategic relevance.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- High
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 5
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A biopharmaceutical company whose long-acting HIV drug lenacapavir underpins both its treatment and prevention franchises. Twice-yearly lenacapavir for PrEP (marketed as Yeztugo) is now available in 10 priority sub-Saharan African countries with a new PEPFAR/Global Fund investment to reach an additional 1 million people, while the FDA granted priority review (PDUFA date August 27, 2026) to a combined bictegravir/lenacapavir once-daily HIV treatment and accepted an application for a once-weekly oral lenacapavir formulation that could become the first long-acting HIV-prevention pill.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Earnings-call mentions
Mentioned by Merck & Co.
“Announced Positive Phase 3 Results From Once-Weekly Investigational Oral HIV Treatment Regimen of Islatravir and Lenacapavir, in Collaboration With Gilead”
SEC 8-K exhibit (0001104659-26-090045) · Aug 4, 2026
Mentioned by Tempus AI
“Expanded our collaboration with Gilead to provide enterprise-wide access to our AI-driven Lens platform and multimodal datasets, aimed at advancing their oncology pipeline through real-world evidence and AI-driven insights.”
SEC 8-K exhibit (0001193125-26-206317) · May 5, 2026
Federal contract disclosures
Department of Health and Human Services — $1,402,138: OFFICE OF INFECTIOUS DISEASE AND HIV/AIDS POLICY (OIDP): ENDING THE HIV EPIDEMIC - PRE-EXPOSURE PROPHYLAXIS (PREP) IMPLEMENTATION AND DISSEMINATION SERVICES
USAspending.gov · Sep 30, 2019
Department of Veterans Affairs — $3,103: SUNLENCA 300MG TAB,PKT,5
USAspending.gov · Jan 28, 2025
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources
- Gilead Sciences — FDA grants priority review of NDA for Gilead's once-daily bictegravir plus lenacapavircompany
- Gilead Sciences — FDA accepts Gilead's application for investigational once-weekly oral Yeztugocompany
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Gilead Sciences — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Gilead is building an entire HIV franchise -- treatment, prevention, injectable, and oral -- around one molecule
33% confidenceLenacapavir now underpins Gilead's HIV strategy across four simultaneous fronts: injectable PrEP (Yeztugo) rolling out across sub-Saharan Africa, a once-daily oral treatment combination (bictegravir/lenacapavir) under FDA priority review, and a once-weekly oral PrEP formulation under FDA review.
This is InsightNodes' own interpretive read: concentrating so much of the HIV franchise's future around a single molecule's various formulations creates significant leverage if all four programs succeed commercially and in global-access rollouts, but it also means any unexpected long-term resistance, safety, or manufacturing issue with lenacapavir itself would ripple across treatment, prevention, injectable, and oral businesses simultaneously -- a different and arguably more concentrated risk profile than Gilead's historically diversified antiretroviral portfolio.
InsightNodes analysis of Gilead 2026 lenacapavir program · Aug 14, 2026
Gilead Sciences's Timeline
A sourced, dated history of Gilead Sciences's key moments — founding to present.
Feb 2026 · Lenacapavir PrEP access expands in South Africa
Gilead, the South African government, and the Global Fund expanded access to twice-yearly lenacapavir for HIV prevention in South Africa, part of a broader rollout across 10 priority sub-Saharan African countries.
Jul 2026 · FDA grants priority review to bictegravir/lenacapavir
The FDA granted priority review to Gilead's New Drug Application for a once-daily combined bictegravir/lenacapavir HIV treatment, with a PDUFA target action date of August 27, 2026.